阿司匹林预防子痫前期的处方策略:成本效果分析
该决策分析比较四种早孕期启动的阿司匹林预防子痫前期策略的成本与效果。结果显示,与普遍使用阿司匹林相比,基于美国预防服务工作组指南、生物标志物与超声筛查及不使用阿司匹林均增加子痫前期病例和医疗成本,普遍使用阿司匹林在所有策略中占优,在蒙特卡洛模拟中91%情况下为首选策略。
要点
- 普遍使用阿司匹林在模拟中91%情况下为首选策略。
- 与普遍使用阿司匹林相比,基于美国预防服务工作组指南策略每10万孕妇增加346例子痫前期,成本增加8,011,725美元。
- 基于生物标志物与超声筛查策略每10万孕妇增加308例子痫前期,成本增加19,216,551美元。
核心结论
- 在广泛假设范围内,普遍使用阿司匹林相较于不使用阿司匹林、基于血清与超声筛查或临床危险因素的阿司匹林使用,与更少的子痫前期病例和更低的成本相关。
研究设计与样本
- 决策分析,比较四种于妊娠16周前启动阿司匹林预防子痫前期的策略的子痫前期相关成本与效果,结果以每10万孕妇的成本和病例数表示。
- 四种策略为:1)不使用阿司匹林;2)基于生物标志物与超声筛查的阿司匹林使用;3)基于美国预防服务工作组指南的阿司匹林使用;4)普遍使用阿司匹林。
- 采用每例子痫前期90,843美元的阈值,进行单因素、双因素和蒙特卡洛敏感性分析,纳入阿司匹林降低风险概率、阿司匹林相关副作用和成本的变化。
主要发现
- 与普遍使用阿司匹林相比,基于美国预防服务工作组指南的策略每10万孕妇增加8,011,725美元医疗成本和346例子痫前期。
- 与普遍使用阿司匹林相比,基于生物标志物与超声筛查的策略每10万孕妇增加19,216,551美元成本和308例子痫前期。
- 与普遍使用阿司匹林相比,不使用阿司匹林每10万孕妇增加18,750,381美元成本和762例子痫前期。
- 在10,000名孕妇的蒙特卡洛模拟中,普遍使用阿司匹林在91%的模拟中为首选策略。
关键数值与推荐
- 普遍使用阿司匹林在91%的模拟中为首选策略;美国预防服务工作组筛查策略在8.5%的模拟中为首选;生物标志物与超声筛查和不用阿司匹林分别在0%和0.5%的模拟中为首选。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the cost effectiveness of various preeclampsia screening and aspirin prophylaxis strategies, including a strategy based on biomarker and ultrasound measures. METHODS: We designed a decision analysis to compare preeclampsia-related costs and effects of four strategies for aspirin use in pregnancy initiated before 16 weeks of gestation to prevent preeclampsia. The four strategies were: 1) no aspirin use, 2) biomarker and ultrasound measure-predicated use, 3) use based on the U.S. Preventive Services Task Force guidelines, and 4) universal aspirin use. Our outcomes were preeclampsia-related costs and number of cases per 100,000 pregnant women. Using a threshold of $90,843 per case of preeclampsia, one-way, two-way, and Monte-Carlo sensitivity analyses incorporating varying probabilities of risk reduction due to aspirin use, aspirin-related side effects, and costs were performed to identify ranges at which costs and risks of aspirin-related complications shifted the preferred strategy. RESULTS: Compared with universal aspirin administration, the use of U.S. Preventive Services Task Force guidelines is associated with $8,011,725 higher health care costs and 346 additional cases of preeclampsia per 100,000 pregnant women; biomarker and ultrasound screening is associated with an additional $19,216,551 and 308 additional cases. Similarly, no aspirin use is associated with an increased cost of $18,750,381 and 762 additional cases. Thus, universal aspirin use dominated all three other strategies. In a Monte Carlo simulation of 10,000 pregnant women, universal aspirin was the preferred strategy in 91% of simulations. The U.S. Preventive Task Force screen was preferred in 8.5% of simulations, and biomarker and ultrasound screening and no aspirin were preferred in 0% and 0.5% of simulations, respectively. CONCLUSION: Over a broad range of assumptions, universal aspirin administration is associated with fewer cases of preeclampsia and fewer costs relative to no aspirin administration and aspirin administration based on serum and ultrasound measures or clinical risk factors.
引用
- Mallampati D, Grobman W, Rouse DJ, et al. Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness Analysis. Obstet Gynecol. 2019. PMID: 31403606. doi:10.1097/AOG.0000000000003413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。